Axogen CEO Axed 25,000 Shares From His Direct Holdings

Company Achievements - Axogen received FDA approval for its unique nerve graft on December 3, 2025, which is a human tissue-based product aimed at repairing damaged peripheral nerves without requiring nerve tissue from patients, granting the company 12 years of market exclusivity [1] - The company is expected to report approximately $225.2 million in annual revenue for FY 2025, marking its highest revenue to date [6] Stock Performance - Axogen's stock (AXGN) experienced a significant increase of 97.60% in 2025, with seven consecutive months of price gains [2] - CEO Michael D. Dale sold 25,000 shares on December 10, 2025, valued at $750,000, which represented 28.24% of his direct holdings prior to the transaction [5] Product and Market Focus - Axogen specializes in surgical solutions for peripheral nerve injuries, developing biologically active nerve grafts, nerve connectors, nerve protectors, nerve caps, and soft tissue membranes for surgical repair and protection of peripheral nerves [3]